201 related articles for article (PubMed ID: 37475487)
1. The aquaporin-4 water channel and updates on its potential as a drug target for Alzheimer's disease.
Silverglate B; Gao X; Lee HP; Maliha P; Grossberg GT
Expert Opin Ther Targets; 2023; 27(7):523-530. PubMed ID: 37475487
[TBL] [Abstract][Full Text] [Related]
2. Targeting the complement system in neuromyelitis optica spectrum disorder.
Asavapanumas N; Tradtrantip L; Verkman AS
Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
[TBL] [Abstract][Full Text] [Related]
3. Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System.
Abe Y; Yasui M
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454180
[TBL] [Abstract][Full Text] [Related]
4. Aquaporin-4 Water Channel in the Brain and Its Implication for Health and Disease.
Mader S; Brimberg L
Cells; 2019 Jan; 8(2):. PubMed ID: 30691235
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapeutic targets for neuromyelitis optica spectrum disorder.
Tradtrantip L; Asavapanumas N; Verkman AS
Expert Opin Ther Targets; 2020 Mar; 24(3):219-229. PubMed ID: 32070155
[No Abstract] [Full Text] [Related]
6. Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders.
Tuller F; Holzer H; Schanda K; Aboulenein-Djamshidian F; Höftberger R; Khalil M; Seifert-Held T; Leutmezer F; Berger T; Reindl M
J Neuroinflammation; 2016 Jul; 13(1):176. PubMed ID: 27371173
[TBL] [Abstract][Full Text] [Related]
7. Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders.
Yick LW; Tang CH; Ma OK; Kwan JS; Chan KH
J Neuroinflammation; 2020 Aug; 17(1):236. PubMed ID: 32782018
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders.
Hinson SR; Lennon VA; Pittock SJ
Handb Clin Neurol; 2016; 133():377-403. PubMed ID: 27112688
[TBL] [Abstract][Full Text] [Related]
9. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.
Cotzomi E; Stathopoulos P; Lee CS; Ritchie AM; Soltys JN; Delmotte FR; Oe T; Sng J; Jiang R; Ma AK; Vander Heiden JA; Kleinstein SH; Levy M; Bennett JL; Meffre E; O'Connor KC
Brain; 2019 Jun; 142(6):1598-1615. PubMed ID: 31056665
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
[TBL] [Abstract][Full Text] [Related]
11. Neuromyelitis optica, aquaporin-4 antibodies, and neuroendocrine disorders.
Iorio R; Papi C
Handb Clin Neurol; 2021; 181():173-186. PubMed ID: 34238456
[TBL] [Abstract][Full Text] [Related]
12. [Actual issues of serum aquaporin-4 autoantibodies evaluation in the diagnostics of neuromyelitis optica spectrum disorders].
Krasnov VS; Totolyan NA; Nazarov VD; Mazing AV; Makshakov GS; Lapin SV; Evdoshenko EP; Skoromets AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(7. Vyp. 2):24-31. PubMed ID: 32844626
[TBL] [Abstract][Full Text] [Related]
13. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
Wu Y; Zhong L; Geng J
Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
[TBL] [Abstract][Full Text] [Related]
15. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Fung S; Shirley M
CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
[TBL] [Abstract][Full Text] [Related]
16. Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review.
Schindler P; Aktas O; Ringelstein M; Wildemann B; Jarius S; Paul F; Ruprecht K
Expert Rev Clin Immunol; 2023 Jan; 19(1):71-91. PubMed ID: 36378751
[TBL] [Abstract][Full Text] [Related]
17. Pathobiology, Diagnosis, and Current Biomarkers in Neuromyelitis Optica Spectrum Disorders.
Fiala C; Rotstein D; Pasic MD
J Appl Lab Med; 2022 Jan; 7(1):305-310. PubMed ID: 34996075
[TBL] [Abstract][Full Text] [Related]
18. The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders.
Stathopoulos P; Dalakas MC
Expert Rev Clin Immunol; 2022 Sep; 18(9):933-945. PubMed ID: 35899480
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Neuromyelitis Optica Spectrum Disorders.
Chan KH; Lee CY
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445343
[TBL] [Abstract][Full Text] [Related]
20. Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders.
Peng S; Liu J; Liang C; Yang L; Wang G
Neurobiol Dis; 2023 Apr; 179():106035. PubMed ID: 36796590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
